Current Adoptive Immunotherapy in Non-Small Cell Lung Cancer and Potential Influence of Therapy Outcome

REFERENCES

• Tucker ZC, Laguna BA, Moon E, Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev 2012.
   PubMedGoogle Scholar
• Saijo N. Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treat Rev 2012;38:194–202.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480–489.
   PubMed Web of Science ®Google Scholar
• Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83–117.
   PubMed Web of Science ®Google Scholar
• Lum LG. T cell-based immunotherapy for cancer: a virtual reality? CA Cancer J Clin 1999;49(2):74–100, 65.
   PubMed Web of Science ®Google Scholar
• Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol 2011.
   PubMedGoogle Scholar
• Custodio A, Mendez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012;38:36–53.
   PubMed Web of Science ®Google Scholar
• Yang K, Wang YJ, Chen XR, Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig 2010;30:229–241.
   PubMed Web of Science ®Google Scholar
• Tomasini P, Khobta N, Greillier L, Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol 2012;4:43–50.
   PubMed Web of Science ®Google Scholar
• Simmons O, Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev Vaccines 2010;9:323–335.
   PubMed Web of Science ®Google Scholar
• Wang J, Zou ZH, Xia HL, Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One 2012;7:e32695.
   PubMedGoogle Scholar
• Ballen K, Stewart FM. Adoptive immunotherapy. Curr Opin Oncol 1997;9:579–583.
   PubMedGoogle Scholar
• Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012.
   PubMed Web of Science ®Google Scholar
• Barrett J, Bollard CM. T-cell therapy for cancer. Immunotherapy 2012;4:347–350.
   PubMed Web of Science ®Google Scholar
• Vera JF, Brenner LJ, Gerdemann U, Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010;33:305–315.
   PubMed Web of Science ®Google Scholar
• Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int J Oncol 2005;27:5–47.
   PubMed Web of Science ®Google Scholar
• Wu R, Forget MA, Chacon J, Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18:160–175.
   PubMed Web of Science ®Google Scholar
• Nguyen LT, Yen PH, Nie J, et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS One 2010;5:e13940.
   PubMedGoogle Scholar
• Hontscha C, Borck Y, Zhou H, Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137:305–310.
   PubMed Web of Science ®Google Scholar
• Mesiano G, Todorovic M, Gammaitoni L, Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012.
   PubMed Web of Science ®Google Scholar
• Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010;2010:435745. doi:10.1155/2010/435745.
   PubMed Web of Science ®Google Scholar
• Hui KM. CIK cells –current status, clinical perspectives and future prospects - the good news. Expert Opin Biol Ther 2012.
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang Z, Tang L, Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012;14:483–493.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu L, Wei J, The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 2012;138:1057–1062.
   PubMed Web of Science ®Google Scholar
• Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009;31:184–196.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Nakajima J, Wada H, Gammadelta T-cell immunotherapy for lung cancer. Surg Today 2011;41:606–611.
   PubMed Web of Science ®Google Scholar
• Liu Z, Eltoum IE, Guo B, Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 2008;180:6044–6053.
   PubMed Web of Science ®Google Scholar
• Riley CL, Mathieu MG, Clark RE, Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother 2009;58:1489–1499.
   PubMed Web of Science ®Google Scholar
• Zhukova OS, Gerasimova GK, Shubina I, Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer. Bull Exp Biol Med 2007;144:231–234.
   PubMed Web of Science ®Google Scholar
• Liu C, Betancourt A, Cohen DA, Granzyme B-mRNA expression by equine lymphokine activated killer (LAK) cells is associated with the induction of apoptosis in target cells. Vet Immunol Immunopathol 2011;143:108–115.
   PubMed Web of Science ®Google Scholar
• Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 1995;13:31–44.
   PubMed Web of Science ®Google Scholar
• Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42–49.
   PubMed Web of Science ®Google Scholar
• Yano T, Sugio K, Yamazaki K, Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 1999;26:143–148.
   PubMed Web of Science ®Google Scholar
• Ebina T, Fujimiya Y. Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein. Lung Cancer 2008;60:246–251.
   PubMed Web of Science ®Google Scholar
• Kilic A, Landreneau RJ, Luketich JD, Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res 2011;167:207–210.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang T, Ye J, Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012;61:1849–1856.
   PubMed Web of Science ®Google Scholar
• Ratto GB, Zino P, Mirabelli S, A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244–251.
   PubMed Web of Science ®Google Scholar
• Amedei A, Niccolai E, Della BC, Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Cancer Immunol Immunother 2009;58:1819–1830.
   PubMedGoogle Scholar
• Dudley ME, Wunderlich JR, Yang JC, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346–2357.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Bernatchez C, Zhang M, Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012.
   Web of Science ®Google Scholar
• Kim HM, Lim J, Park SK, Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007;7:1802–1807.
   PubMed Web of Science ®Google Scholar
• Li H, Wang C, Yu J, Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009;11:1076–1083.
   PubMed Web of Science ®Google Scholar
• Li R, Wang C, Liu L, Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012.
   Web of Science ®Google Scholar
• Wu C, Jiang J, Shi L, Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008;28:3997–4002.
   PubMed Web of Science ®Google Scholar
• Iwai K, Soejima K, Kudoh S, Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. Cancer Immunol Immunother 2012.
   PubMed Web of Science ®Google Scholar
• Zhou JH, Kang N, Cui LX, Selection of culture media for the mass production of gammadelta T cells used in adoptive immunotherapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011;33:644–648.
   PubMedGoogle Scholar
• Zhou J, Kang N, Cui L, Anti-gammadelta TCR antibody-expanded gammadelta T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 2012;9:34–44.
   PubMed Web of Science ®Google Scholar
• Kondo M, Sakuta K, Noguchi A, Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842–856.
   PubMed Web of Science ®Google Scholar
• Kang N, Zhou J, Zhang T, Adoptive immunotherapy of lung cancer with immobilized anti-TCR gammadelta antibody-expanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 2009;8:1540–1549.
   PubMed Web of Science ®Google Scholar
• Dokouhaki P, Han M, Joe B, Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 2010;297:126–136.
   Google Scholar
• Sakamoto M, Nakajima J, Murakawa T, Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 2011;34:202–211.
   PubMed Web of Science ®Google Scholar
• Hanagiri T, Shigematsu Y, Kuroda K, Anti-tumor activity of human gammadelta T cells transducted with CD8 and with T cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci 2012.
   PubMed Web of Science ®Google Scholar
• Nakajima J, Murakawa T, Fukami T, A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37:1191–1197.
   PubMed Web of Science ®Google Scholar
• Zhong R, Teng J, Han B, Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011;60:1497–1502.
   PubMed Web of Science ®Google Scholar
• Yang L, Ren B, Li H, Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2012.
   Web of Science ®Google Scholar
• Shi SB, Ma TH, Li CH, Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012;98:314–319.
   PubMed Web of Science ®Google Scholar
• Kimura H, Iizasa T, Ishikawa A, Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 2008;28:1229–1238.
   PubMed Web of Science ®Google Scholar
• Motohashi S, Nagato K, Kunii N, A phase I–II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009;182:2492–2501.
   PubMed Web of Science ®Google Scholar
• Iliopoulou EG, Kountourakis P, Karamouzis MV, A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1781–1789.
   PubMed Web of Science ®Google Scholar
• Ratto GB, Costa R, Maineri P, Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study. Int J Immunopathol Pharmacol 2011;24:1005–1016.
   PubMed Web of Science ®Google Scholar
• Sun Z, Shi L, Zhang H, Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol 2011;138:23–32.
   PubMed Web of Science ®Google Scholar
• Siebert JC, Walker EB. Monitoring cytokine profiles during immunotherapy. Immunotherapy 2010;2:799–816.
   Google Scholar
• Bonanno G, Iudicone P, Mariotti A, Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med 2010;8:129.
   PubMed Web of Science ®Google Scholar
• Johansson A, Hamzah J, Payne CJ, Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 2012;109:7841–7846.
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Bertetto O, Santo A, Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol 2011;39:1011–1017.
   PubMed Web of Science ®Google Scholar
• Lefebvre JS, Maue AC, Eaton SM, The aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice. Aging Cell 2012.
   PubMed Web of Science ®Google Scholar
• Joseph RW, Peddareddigari VR, Liu P, Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 2011;17:4882–4891.
   PubMed Web of Science ®Google Scholar
• Albright JW, Bream JH, Bere EW, Aging of innate immunity: functional comparisons of NK/LAK cells obtained from bulk cultures of young and aged mouse spleen cells in high concentrations of interleukin-2. Exp Gerontol 2004;39:73–82.
   PubMed Web of Science ®Google Scholar
• Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641–648.
   PubMed Web of Science ®Google Scholar
• Kato M, Goto S, Soma G. Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma. Anticancer Res 2010;30:3125–3128.
   PubMed Web of Science ®Google Scholar
• Lu T, Ramakrishnan R, Altiok S, Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011;121:4015–4029.
   PubMed Web of Science ®Google Scholar
• Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243–265.
   PubMed Web of Science ®Google Scholar
• Yao X, Ahmadzadeh M, Lu YC, Levels of peripheral CD4 + FoxP3 + regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012.
   Web of Science ®Google Scholar
• Nagaraj S, Schrum AG, Cho HI, Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106–3116.
   PubMed Web of Science ®Google Scholar
• Salagianni M, Lekka E, Moustaki A, NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol 2011;186:3327–3335.
   Google Scholar
• Kodumudi KN, Weber A, Sarnaik AA, Blockade of myeloid-derived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 2012;189:5147–5154.
   PubMed Web of Science ®Google Scholar
• Peng S, Lyford-Pike S, Akpeng B, Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 2013;62:171–182.
   PubMed Web of Science ®Google Scholar
• Son CH, Shin DY, Kim SD, Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model. J Immunother 2012;35:607–614.
   PubMed Web of Science ®Google Scholar
• Pan PY, Ma G, Weber KJ, Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99–108.
   PubMed Web of Science ®Google Scholar
• Thanendrarajan S, Nowak M, Abken H, Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011;35:1136–1142.
   PubMed Web of Science ®Google Scholar
• Wang QJ, Wang H, Pan K, Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 2010;29:641–648.
   PubMedGoogle Scholar
• Valteau-Couanet D, Leboulaire C, Maincent K, Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002;100:2554–2561.
   PubMed Web of Science ®Google Scholar
• West EJ, Scott KJ, Jennings VA, Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. Br J Cancer 2011;105:787–795.
   PubMed Web of Science ®Google Scholar
• Li Q, Lao X, Pan Q, Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011;17:4987–4995.
   PubMed Web of Science ®Google Scholar
• Li Q, Teitz-Tennenbaum S, Donald EJ, In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009;183:3195–3203.
   PubMed Web of Science ®Google Scholar
• Huang X, Chen YT, Song HZ, Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells. World J Gastroenterol 2011;17:3002–3011.
   PubMed Web of Science ®Google Scholar
• Chen J, Huang X, Huang G, Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokine-induced killer cells in a murine melanoma model. Cancer Biother Radiopharm 2012;27:210–220.
   PubMed Web of Science ®Google Scholar
• Teitz-Tennenbaum S, Li Q, Davis MA, Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother 2009;32:602–612.
   Google Scholar
• Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012;12:565–572.
   PubMed Web of Science ®Google Scholar
• Li XD, Xu B, Wu J, Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012;14:102–108.
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Tey SK, Dotti G, Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673–1683.
   PubMed Web of Science ®Google Scholar
• Petersen RP, Campa MJ, Sperlazza J, Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866–2872.
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang T, Ye J, Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012.
   Web of Science ®Google Scholar
• Ito N, Suzuki Y, Taniguchi Y, Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005;25:2027–2031.
   PubMed Web of Science ®Google Scholar
• Kuo CH, Lo CY, Chung FT, Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. PLoS One 2012;7:e33226.
   Web of Science ®Google Scholar
• Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 2011;61:91–112.
   PubMed Web of Science ®Google Scholar
• Fox BA, Schendel DJ, Butterfield LH, Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011;9:214.
   PubMed Web of Science ®Google Scholar